Comparative Pharmacology
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus MUCINEX D.
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
Expectorant/Antitussive Combination
Expectorant/Decongestant Combination